Wynn Capital LLC purchased a new position in Medtronic plc (NYSE:MDT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,450 shares of the medical technology company’s stock, valued at approximately $202,000.
Other institutional investors have also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new position in shares of Medtronic in the fourth quarter worth $25,000. Hartford Financial Management Inc. increased its stake in Medtronic by 425.0% in the third quarter. Hartford Financial Management Inc. now owns 315 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 255 shares during the last quarter. Financial Gravity Asset Management Inc. boosted its position in Medtronic by 317.0% during the third quarter. Financial Gravity Asset Management Inc. now owns 367 shares of the medical technology company’s stock valued at $29,000 after buying an additional 279 shares during the period. Princeton Global Asset Management LLC purchased a new stake in Medtronic during the third quarter valued at about $31,000. Finally, Rakuten Securities Inc. purchased a new stake in Medtronic during the fourth quarter valued at about $49,000. Institutional investors own 82.06% of the company’s stock.
Insider Buying and Selling
In related news, EVP Michael Marinaro sold 854 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $83.14, for a total value of $71,001.56. Following the completion of the transaction, the executive vice president now directly owns 27,925 shares in the company, valued at approximately $2,321,684.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Medtronic news, EVP Michael Marinaro sold 854 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $83.14, for a total transaction of $71,001.56. Following the completion of the sale, the executive vice president now directly owns 27,925 shares in the company, valued at approximately $2,321,684.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Sean Salmon sold 30,695 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $85.13, for a total transaction of $2,613,065.35. Following the sale, the executive vice president now directly owns 48,289 shares of the company’s stock, valued at approximately $4,110,842.57. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on MDT
Medtronic Stock Down 1.5 %
Shares of MDT stock traded down $1.17 during trading hours on Thursday, hitting $79.21. 1,815,536 shares of the company’s stock traded hands, compared to its average volume of 6,216,978. The stock’s fifty day simple moving average is $83.73 and its two-hundred day simple moving average is $81.14. Medtronic plc has a 12-month low of $68.84 and a 12-month high of $92.02. The stock has a market cap of $105.18 billion, a price-to-earnings ratio of 25.60, a PEG ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.71, a current ratio of 2.30 and a debt-to-equity ratio of 0.46.
Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, February 20th. The medical technology company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.04. Medtronic had a net margin of 13.00% and a return on equity of 13.71%. The firm had revenue of $8.09 billion during the quarter, compared to analyst estimates of $7.95 billion. During the same period last year, the business earned $1.30 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. On average, analysts expect that Medtronic plc will post 5.2 EPS for the current year.
Medtronic Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 12th. Investors of record on Friday, March 22nd were issued a $0.69 dividend. The ex-dividend date was Thursday, March 21st. This represents a $2.76 dividend on an annualized basis and a yield of 3.48%. Medtronic’s payout ratio is currently 87.90%.
Medtronic Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More
- Five stocks we like better than Medtronic
- Industrial Products Stocks Investing
- Hasbro’s Management Made All the Right Calls This Quarter
- Why Are Stock Sectors Important to Successful Investing?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What Are Growth Stocks and Investing in Them
- Power Surge: Utilities Sector’s Resilience Shines
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.